There was just a new site opened for the early/expanded access program for Alpharedin (Radium-235). The new site is at Stanford University, California. This makes a total of four sites, but most of them have not been adequately supported by the drug company, Bayer. Hopefully, this site will be better supported, but if it too [...]
It is the general consensus that prostate cancer when still confined to the prostate gland is gland curable, but when it has left the prostate gland and becoming metastatic it is no longer curable. But evidence now says there might be an intermediate stage where the cancer has spread outside the prostate gland but is [...]
The FDA has approved c11 choline Injection, a Positron Emission Tomography (PET) imaging agent, for use in men to detect prostate cancer recurrences and to locate specific body sites for follow-up tissue sampling, testing and treatment. The indicated use for c11 choline injection is men with elevated prostate specific antigen (PSA) levels after earlier primary [...]
In a study conducted by Choueiri et al. published in Cancer it was suggested that men who have prostate cancer that was treated by a radical prostatectomy (RP) who then had a long time to a biochemical recurrence (BCR) or a long PSA doubling time after a BCR have no higher overall risk of death [...]